During the years from 1993 to 2000, 183 strains of Pseudomonas aeruginosa were isolated from different pathological specimens originating from dogs. Antimicrobial susceptibility patterns against 10 antipseudomonal agents were obtained on 183 P. aeruginosa strains. In vitro antimicrobial susceptibility testing was performed using the disk diffusion method (KirbyBauer). Antimicrobial susceptibility profiles showed that among b-lactam antibiotics, imipenem was the most active compound. Out of the 183 strains tested, 96.7% were sensitive to imipenem. Cefoperazone showed good in vitro activity against 86.9% of the tested strains. Against ceftazidime, 77.0% of strains showed sensitivity. An old penicillin, carbenicillin, gave only 71.6% sensitive strains. Sensitivity to amikacin was 87.4% and it was 83.1% to gentamicin. Pipimedic acid, a firstgeneration quinolone, was the least active compound of all those tested, 47.0% were resistant. The in vitro sensitivity against enrofloxacin showed that 71.0% strains were sensitive and 26.2% showed resistance. Almost all strains tested, 93.4%, were susceptible to ciprofloxacin and marbofloxacin. Besides imipenem, the quinolone antibiotics, marbofloxacin and ciprofloxacin were the most effective against P. aeruginosa strains isolated from dogs.
Introduction
Pseudomonas aeruginosa is a Gram-negative, glucose-nonfermenting aerobic bacterium. It is the epitome of an opportunistic pathogen of humans and animals and is rarely involved in primary disease. The pathogenesis of Pseudomonas infections is multifactoral, and connected by the number and wide array of virulence determinants possessed by the bacterium (Quinn et al., 1994) . Pseudomonas aeruginosa can be cultured from the normal tissues of healthy animals, including gut, nasal cavity, mouth, tonsils, oral pharynx, distal urethra, prepuce, semen, vagina and conjunctiva (Greene, 1998) . In animals, P. aeruginosa has been assigned as the distinct cause of infections such as otitis externa (Blue and Wooley, 1977; Mueller and Heusinger, 1994; Kiss et al., 1997; Colombini et al. 2000) , cystitis, endocarditis, dermatitis, wound infections, conjunctivitis, equine metritis and ulcerative keratoconjunctivitis, mink haemorrhagic pneumonia, deep pyoderma, infections of the lower urinary tract (Rorich et al., 1983) , prostatitis, osteomyelitis, chronic rhinitis, pleuritis, mastitis (Coats, 1998) septicaemia (Court et al., 1994) , and bacterial endocarditis (Greene, 1998) . It is notorious for its resistance to antibiotics and is therefore a particularly dangerous and dreaded pathogen. This bacterium is uniformly resistant to ampicillins, first-and second-generation cephalosporins, erythromycin and is also often resistant to streptomycin, tetracyclines, chloramphenicol, sulphonamides, cotrimoxazole, nitrofurantoine and fluoroquinolones. (Aires et al., 1999) . Among the b-lactam antibiotics, new penicillins, including azlocillin, are more active than carbenicillin and some thirdgeneration cephalosporins, notably cefoperazon, ceftazidime and cefsulodin, also exhibit anti-Pseudomonas activity. Fluoroquinolones, especially enrofloxacin, have been used extensively during the past 10 years in veterinary dermatology, predominantly for the management of canine pyoderma and in the management of canine otitis externa and otitis media caused by P. aeruginosa (Ihrke et al., 1999) . Approximately 40% of enrofloxacin is metabolized to ciprofloxacin and this active metabolite is further biotransformed to several additional compounds that are excreted primarily in urine (Cester and Toutain, 1997) . Ciprofloxacin was shown to be the most potent quinolone against P. aeruginosa (Walker, 1999) . Recently, marbofloxacin, was developed for veterinary medicine. Marbofloxacin has shown a broad-spectrum bactericidal activity against numerous Gram-negative and Gram-positive bacteria, including mycoplasmas. It has also exhibited marked post-antibiotic effects, both in vivo and ex vivo, so it is suitable for use in wide range of clinical situations in dogs and cats (Spreng et al., 1995; Drugeon and Thomas, 1997; Thomas et al., 1997; Weber et al. 2000; Barrasa et al. 2000) .
The present study investigated the in vitro antimicrobial susceptibility of 183 canine P. aeruginosa isolates against 10 antipseudomonal agents.
Materials and Methods
During the period from 1993 to 2000, 3184 specimens taken from dogs visiting The Clinics of the Veterinary Faculty at the University of Zagreb, were submitted to microbiological examination. Among them, 1230 swabs were taken from horizontal ear canals of dogs suffering from otitis. The rest of the specimens were taken from different body sites of diseased dogs. During that period, a total of 183 P. aeruginosa strains were isolated. Identification of P. aeruginosa was carried out according to the procedure described by Quinn et al. (1994) . In the present study, 183 P. aeruginosa isolates were tested by the Kirby-Bauer's disk diffusion method on Mueller-Hinton agar (Prescott and Baggot, 1993 1 ) for antimicrobial susceptibility against 10 antipseudomonal agents: imipenem (10 lg), carbenicillin (100 lg), ceftazidime (30 lg), cefoperazone (30 lg),
amikacin (30 lg), gentamicin (10 lg), pipimedic acid (20 lg), enrofloxacin (5 lg) and ciprofloxacin (5 lg). Sensitivity to marbofloxacin (5 lg), was determined afterwards on all strains from our collection. A standard concentration of a pure culture of P. aeruginosa was placed on Mueller-Hinton agar (Becton Dickinson, Cockeysville, 2 USA), and individual filter paper disks containing known concentrations of individual antibiotics were placed on the pathogen. The culture was incubated for 18-24 h at 37°C. The zone of inhibition around each disk was measured, and the measurement was compared to the chart presented in Table 1 . This classified the organism into one of three categories: sensitive, resistant and intermediate sensitive.
Results
In the period from 1993 to 2000, 3184 specimens originating from dogs were submitted to microbiological examination and a total of 183 P. aeruginosa strains were isolated. The majority of the 183 P. aeruginosa strains included in the present study originated from horizontal ear canals (106 isolates) and skin (40 isolates). More than half of the isolated strains originated from Cocker spaniels. The results of P. aeruginosa isolations according to site of isolation are given in Table 2 . Besides P. aeruginosa, the most frequently isolated bacterial species was Staphylococcus intermedius (487 isolates). Some other microorganisms were also found, e.g. Proteus sp., Streptococcus sp., Staphylococcus aureus, Staphylococcus sp. (coagulase-negative), Bacillus sp., Escherichia coli, Malasezzia pachydermatis and Candida sp. (226 isolates) which were not further investigated. Antimicrobial susceptibility profiles showed that among b-lactam antibiotics, imipenem was the most active compound. Out of the 183 tested strains, 177 strains (96.7%) were sensitive and only four strains (2.2%) were resistant, while two strains (1.1%) were intermediately sensitive. A thirdgeneration cephalosporin, cefoperazone showed a very good in vitro activity against 159 (86.9%) tested strains, 15 (8.2%) strains were resistant and nine strains (4.9%) had intermediate sensitivity. Against ceftazidime 141 strains (77.0%) showed 
Discussion
In the present study the antimicrobial susceptibility of 183 P. aeruginosa of canine origin was tested against three groups of anti-pseudomonal agents: b-lactams: imipenem, cefoperazone, ceftazidime and carbenicillin; aminoglycosides: amikacin and gentamicin; and fluoroquinolones: pipimedic acid, enrofloxacin, ciprofloxacin and marbofloxacin. Among the b-lactams imipenem was the most active compound. Out of 183 tested strains, 96.7% were sensitive and only 2.2% isolates were resistant. Similar results were obtained by MuellerPremru and Gubina (2000) , Panayotis et al. (1998) and Spencer (1996) in human P. aeruginosa isolates. In contrast, Watanabe et al. (1992) tested 334 clinical isolates against imipenem and found 23.4% resistant strains. Of the two thirdgeneration cephalosporins in our study, cefoperazone showed higher activity than ceftazidime. Against ceftazidime 19.7% of tested strains showed resistance, while only 8.2% were resistant to cefoperazone. Relatively high resistance to ceftazidime was obtained by Watanabe et al. (1992) , with 28% resistant strains. The susceptibility rates for ceftazidime on in vitro sensitivity testing reported by other authors were much higher. Mueller-Premru and Gubina (2000) tested 208 isolates from humans and found only 9.1% strains resistant to ceftazidime, and Spencer (1996) showed that out of 29 425 P. aeruginosa isolates, 95% were sensitive. Higher resistance to ceftazidime was observed by Shawar et al. (1999) , with 11.1% resistant strains of 1240 tested, and Panayotis et al. (1998) who found 15% resistance against ceftazidime in 88 non-replicate nosocomial P. aeruginosa strains. The less active b-lactam was carbenicillin, against which 21.9% isolates were resistant. Colombini et al. (2000) investigated the in vitro sensitivity of 38 P. aeruginosa strains isolated from dogs suffering from otitis media and found a lower resistance rate to carbenicillin, with only 19%. There were no significant differences in sensitivity or resistance against the two tested aminoglycosides, amikacin and gentamicin, even though amikacin showed higher activity against P. aeruginosa than gentamicin. Sensitivity to amikacin was found in 87.4% isolates versus 83.1% sensitivity against gentamicin. Against amikacin, 7.6% strains showed resistance and 10.9% of them were resistant to gentamicin. Intermediate sensitivity to both aminoglycosides was similar: 4.9% to amikacin and 6.0% to gentamicin. Shawar et al. (1999) Shawar et al. (1999) . In contrast, Spencer (1996) in an 8-year survey of 29 425 hospital P. aeruginosa isolates found 95% susceptibility to ciprofloxacin. The higher susceptibility to ciprofloxacin of our P. aeruginosa isolates is probably due to its very limited use in veterinary practice in Croatia. Enrofloxacin showed a relatively low activity against P. aeruginosa isolates compared to ciprofloxacin and marbofloxacin but also higher compared to the results of other authors. Those results are very interesting because enrofloxacin is in extensive use in the therapy of bacterial infections in small animals, especially dogs, suffering from otitis and/or skin disorders without prior antimicrobial susceptibility testing. A study by Cole et al. (1998) demonstrated that only 12.5% of Pseudomonas spp. isolates from the horizontal ear canal, and 35% of isolates from the middle ear canal were susceptible to enrofloxacin. Cole, [in a personal communication to Ihrke et al. (1999) ], mentioned that 50% of canine isolates were resistant to enrofloxacin. Barrasa et al. (2000) tested 19 P. aeruginosa isolates and found 42.1% resistant strains to enrofloxacin. Colombini et al. (2000) tested 37 Pseudomonas isolates, of which 49% were resistant to enrofloxacin. The Vetoquinol group, Cedex, France (Charles-Eric Descotes, personal communication) in P. aeruginosa epidemiosurvey 2000, tested 52 canine isolates and only 29% were susceptible to enrofloxacin. The in vitro sensitivity testing for marbofloxacin, included in the investigation afterwards, showed that 93.4% canine isolates were sensitive, 4.4% were resistant and 2.2% were intermediate sensitive. Barrasa et al. (2000) tested 19 P. aeruginosa isolates against marbofloxacin and found 89.9% sensitive strains, 9% were resistant and 1.1% showed intermediate sensitivity. Weber et al. (2000) investigated 31 P. aeruginosa and 27 Pseudomonas sp. isolates. They found that 83.9% of P. aeruginosa were susceptible to marbofloxacin and only Antimicrobial Susceptibility of P. aeruginosa Strains in Dogs 3 Frazier et al. (2000) showed that among marbofloxacin, enrofloxacin (including its active metabolite ciprofloxacin) and difloxacin, marbofloxacin has greater C max (maximum plasma drug concentration curve lg/ml · h) and ACU 0-last (the area under the plasma drug concentration versus time curve lg/ml · h) compared with enrofloxacin, ciprofloxacin, enrofloxacin plus ciprofloxacin combined, or difloxacin. Those results suggest that even though ciprofloxacin showed better activity than enrofloxacin and similarly activity to marbofloxacin, because of its pharmacokinetic properties, marbofloxacin should be the quinolone of choice. It is interesting to mention that one P. aeruginosa strain, isolated from the horizontal ear canal of dog, showed a multiple resistance to all quinolone antibiotics as well as against imipenem, carbenicillin and ceftazidime. Although not so common, multiple resistance of Gram-negative bacteria against fluoroquinolone antibiotics has already been noted (Thomson, 1999) . It should also be pointed out that the majority of the isolated strains, 106 of them, originated from the horizontal ear canal and over half of the isolates originated from Cocker spaniels. We presume that some genetic background causes a predisposition to such a high rate of ear infections caused predominantly by P. aeruginosa. Cole et al. (1998) evaluating otitis externa in 82 dogs found that Cocker spaniels represented 48.8%v (40/82) of the dogs, while P. aeruginosa was isolated from only two Cocker spaniels. Besides this mentioned study there were no data in the literature connecting Cocker spaniels and otitis externa-media caused by P. aeruginosa.
